Aliskiren/amlodipine Disease Interactions
There are 7 disease interactions with aliskiren / amlodipine.
- Diabetes
- Cardiogenic shock/hypotension
- Coronary artery disease
- Liver disease
- Hypotension
- Renal impairment
- CHF/AMI
Aliskiren (applies to aliskiren/amlodipine) diabetes
Major Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus
The use of aliskiren is contraindicated in patients with diabetes who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), as there is an increased risk of renal impairment, hyperkalemia, and hypotension.
CCBs (applies to aliskiren/amlodipine) cardiogenic shock/hypotension
Major Potential Hazard, High plausibility. Applicable conditions: Aortic Stenosis
In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock. Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients. The use of verapamil and diltiazem is specifically contraindicated under these circumstances.
CCBs (applies to aliskiren/amlodipine) coronary artery disease
Major Potential Hazard, Low plausibility. Applicable conditions: Ischemic Heart Disease
Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations. The mechanism of this effect is not established. Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.
CCBs (applies to aliskiren/amlodipine) liver disease
Major Potential Hazard, High plausibility.
Calcium channel blockers (CCBs) are extensively metabolized by the liver. The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation. In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin. While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury. Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function. Periodic monitoring of liver function is advised.
Aliskiren (applies to aliskiren/amlodipine) hypotension
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Dehydration, Hyponatremia
Symptomatic hypotension may occur after treatment initiation with aliskiren in patients with marked volume depletion, salt depletion, or with combined use of aliskiren and other agents acting on the renin-angiotensin-aldosterone system. It is recommended to correct the volume or salt depletion before administering aliskiren. Close monitoring is recommended.
Aliskiren (applies to aliskiren/amlodipine) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Congestive Heart Failure, History - Myocardial Infarction
Renal function should be monitored periodically in patients treated with aliskiren, as changes can occur including acute renal failure. Patients on aliskiren whose renal function may depend in part of the RAAS (renin-angiotensin-aldosterone system), such as patients with renal artery stenosis, severe heart failure, or postmyocardial infarction may be at higher risk for developing acute renal failure. Treatment should be discontinued in any patients who develop clinically significant decrease in renal function. Patients with renal impairment should be observed closely. The safety and effectiveness of aliskiren have not been established in patients with severe renal impairment (CrCl < 30 mL/min), as these patients were excluded from clinical trials.
CCBs (applies to aliskiren/amlodipine) CHF/AMI
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Congestive Heart Failure, Myocardial Infarction
Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect. Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil. Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction. Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker. Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.
Switch to professional interaction data
Aliskiren/amlodipine drug interactions
There are 620 drug interactions with aliskiren / amlodipine.
Aliskiren/amlodipine alcohol/food interactions
There are 4 alcohol/food interactions with aliskiren / amlodipine.
More about aliskiren / amlodipine
- aliskiren/amlodipine consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: miscellaneous antihypertensive combinations
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Lasix
Lasix is a loop diuretic used to treat fluid retention from heart, liver, or kidney conditions, and ...
Labetalol
Labetalol systemic is used for high blood pressure, hypertensive emergency, mitral valve prolapse ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Lisinopril
Lisinopril is an ACE inhibitor. It is used to treat high blood pressure, congestive heart failure ...
Vasotec
Vasotec (enalapril) is used to treat high blood pressure, heart failure and kidney problems caused ...
Valsartan
Valsartan is an angiotensin II receptor blocker (ARB) that may be used to treat high blood pressure ...
Hydrochlorothiazide
HCTZ (hydrochlorothiazide) used to treat high blood pressure (hypertension) and edema. Includes ...
Atenolol
Atenolol is used to treat angina (chest pain) and hypertension (high blood pressure). Learn about ...
Furosemide
Furosemide is a loop diuretic used to treat fluid retention and high blood pressure by increasing ...
Metoprolol
Metoprolol is used to treat angina (chest pain) and hypertension (high blood pressure). Learn about ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.